Population genomics research initiatives lead to improved health care for patients with complex and rare inherited diseases, as well as cancer, and have the potential to provide real economic benefit to participating nations.
As a global leader in genomic sequencing and comprehensive analytics services, Personalis is uniquely suited to lead these population-scale efforts. Operating one of the largest genomics and analytics labs in the U.S., we provide genomic solutions spanning from translational research to clinical applications for more than 100 pharma customers worldwide, as well as whole genome sequencing (WGS) for the U.S. Veterans Health Administration. Personalis delivers high quality, factory-scale sequencing to help your program navigate the journey of enabling precision health in your population. Currently, we are also in the process of expanding business operations internationally.
With the help of our world-class scientists, engineers, bioinformaticians, and project managers, we are committed to helping our partners achieve their study goals. Sharing in our expertise in sample management, extraction, sequencing, analytics, computation, and storage, along with data sharing and security, our partners can expect the utmost level of support and guidance to accelerate their population studies.
Personalis has strong relationships with top pharma companies using our ImmunoID NeXT Platform for oncology applications. Our dedicated population genomics team with pharmaceutical partnering experience can help foster research relationships and drug discovery partnerships to benefit patients from your cohorts in the future.